T
Thomas D. Schmittgen
Researcher at University of Florida
Publications - 119
Citations - 177830
Thomas D. Schmittgen is an academic researcher from University of Florida. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 48, co-authored 111 publications receiving 150512 citations. Previous affiliations of Thomas D. Schmittgen include University of Southern California & University of Oklahoma.
Papers
More filters
Journal ArticleDOI
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Björn Hackanson,Kristi L. Bennett,Romulo M. Brena,Jinmai Jiang,Rainer Claus,Rainer Claus,Shih Shih Chen,Nadya Blagitko-Dorfs,Katie Maharry,Katie Maharry,Susan P. Whitman,Thomas D. Schmittgen,Michael Lübbert,Guido Marcucci,Clara D. Bloomfield,Christoph Plass +15 more
TL;DR: It is shown that C/EBP alpha mRNA is a target for miRNA-124a, a computational microRNA prediction approach and functional studies that shows that this miRNA is frequently silenced by epigenetic mechanisms in leukemia cell lines, becomes up-regulated after epigenetic treatment, and targets the C/ EBP alpha 3' untranslated region.
Journal ArticleDOI
Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts.
Donald E. Kuhn,Gerard J. Nuovo,Mickey M. Martin,Geraldine E. Malana,Adam Pleister,Jinmai Jiang,Thomas D. Schmittgen,Alvin V. Terry,Katheleen Gardiner,Elizabeth Head,David S. Feldman,Terry S. Elton +11 more
TL;DR: It is hypothesized that trisomic 21 gene dosage overexpression of Hsa21-derived miRNAs results in the decreased expression of specific target proteins and contribute, in part, to features of the neuronal and cardiac DS phenotype.
Journal ArticleDOI
microRNA Replacement Therapy for Cancer
TL;DR: The field of oligonucleotide mimics and gene vector approaches to restore microRNA levels in tumors is surveyed and the literature on experimental and pre-clinical studies that have used these approaches to treat cancer is reviewed.
Journal ArticleDOI
miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.
Jon C. Henry,Jong Kook Park,Jinmai Jiang,Ji Hye Kim,David M. Nagorney,Lewis R. Roberts,Soma Banerjee,Thomas D. Schmittgen +7 more
TL;DR: The ability of miR-199a-3p to selectively kill CD44+ HCC may be a useful targeted therapy for CD44 + HCC.
Journal ArticleDOI
A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets.
Gerard J. Nuovo,Terry S. Elton,Patrick Nana-Sinkam,Stefano Volinia,Carlo M. Croce,Thomas D. Schmittgen +5 more
TL;DR: This protocol describes in situ miRNA detection that can be done in paraffin-embedded, formalin-fixed tissue and involves colabeling by immunohistochemistry for the putative target of the miRNA.